Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · Real-Time Price · USD
15.95
+0.08 (0.50%)
Feb 20, 2026, 4:00 PM EST - Market closed
Summit Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
159
Market Cap
12.30B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 705.00K | -1.10M | -61.03% |
| Dec 31, 2021 | 1.81M | 949.00K | 110.35% |
| Dec 31, 2020 | 860.00K | -96.00K | -10.04% |
| Dec 31, 2019 | 956.00K | - | - |
| Jan 31, 2019 | 956.00K | - | - |
| Jan 31, 2018 | 956.00K | -1.94M | -67.04% |
| Jan 31, 2017 | 2.90M | - | - |
| Jan 31, 2013 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jazz Pharmaceuticals | 4.16B |
| BioMarin Pharmaceutical | 3.09B |
| Exelixis | 2.32B |
| Halozyme Therapeutics | 1.24B |
| Ionis Pharmaceuticals | 966.96M |
| Ascendis Pharma | 845.52M |
| Madrigal Pharmaceuticals | 740.64M |
| Axsome Therapeutics | 561.26M |
SMMT News
- 2 days ago - Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026 - Business Wire
- 20 days ago - Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 22 days ago - Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy - Business Wire
- 5 weeks ago - Summit Therapeutics Inc. (SMMT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 5 weeks ago - Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK's B7-H3 Antibody Drug Conjugate (ADC) - Business Wire
- 5 weeks ago - Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC - Business Wire
- 6 weeks ago - Summit Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 2 months ago - Summit Therapeutics Inc. (SMMT) Presents at Evercore 8th Annual Healthcare Conference Transcript - Seeking Alpha